Literature DB >> 30643575

Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.

Valentina Bertaglia1,1, Stefania Vallone2,2, Maria Vittoria Pacchiana1,1, Silvia Novello1,1.   

Abstract

Lung cancer is the leading cause of cancer-related deaths in worldwide, and NSCLC represents around 85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the second most common subtype and it is challenging to treat. New options have been discovered but progresses are still limited for the lack of 'druggable' mutations. Specific resources for SqCLC are limited and this condition affects treatment and outcomes. This paper describes available and emerging therapeutic options and resources that may help patients to face their disease. We have also performed a monocentric survey collecting information about smoking habit and sense of guilty and analyzed the possibility for patients to find helpful sources for their disease. The results suggest that more materials focused on SqCLC are still needed.

Entities:  

Keywords:  squamous cell lung cancer; therapeutic options; unmet needs

Year:  2017        PMID: 30643575      PMCID: PMC6310352          DOI: 10.2217/lmt-2017-0011

Source DB:  PubMed          Journal:  Lung Cancer Manag        ISSN: 1758-1966


  3 in total

1.  Association of Diabetes Severity and Mortality with Lung Squamous Cell Carcinoma.

Authors:  Chih-Hsiung Su; Wan-Ming Chen; Mingchih Chen; Ben-Chang Shia; Szu-Yuan Wu
Journal:  Cancers (Basel)       Date:  2022-05-22       Impact factor: 6.575

2.  Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.

Authors:  Erkhem-Ochir Bilguun; Kyoichi Kaira; Reika Kawabata-Iwakawa; Susumu Rokudai; Kimihiro Shimizu; Takehiko Yokobori; Tetsunari Oyama; Ken Shirabe; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

3.  Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma.

Authors:  Xiran He; Yang Du; Zhijie Wang; Xin Wang; Jianchun Duan; Rui Wan; Jiachen Xu; Pei Zhang; Di Wang; Yanhua Tian; Jiefei Han; Kailun Fei; Hua Bai; Jie Tian; Jie Wang
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.